Market Closed -
Japan Exchange
11:30:00 05/07/2024 am IST
5-day change
1st Jan Change
1,354
JPY
-4.04%
-4.92%
-20.26%
Shin Nippon Biomedical Laboratories : Supplementary Material on Quarterly Financial Results
February 02, 2022 at 11:39 am IST
The 3rd Quarter of the Fiscal Year Ending March 31, 2022
Supplementary Material on Quarterly
Financial Results
February 2, 2022
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
（ TSE 1st Section: 2395）
Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.
1. Outline of Q3 Consolidated Financial Results
株式会社新日本科学 Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 1
Financial Results Highlights: Q3 FY2022/3
Set new record highs again for operating profit, ordinary profit and profit attributable to owners of parent
FY2022/3
Q3 Results
Yoy
Net sales
129.4
+25.2
Operating Profit
33.0
+16.7
Ordinary Profit
46.8
+30.3
Profit Attributable to
52.4
+37.7
Owners of Parent
（ 100 million of yen）
Net sales
Ordinary
Profit
129.4
46.8
104.2
16.4
FY21/3
FY22/3
FY21/3
FY22/3
Q3
Q3
Q3
Q3
（ 100 million of yen）
株式会社新日本科学 Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 2
Yoy Comparison of Consolidated Ordinary Profit & Loss: Q3 FY2022/3
Ordinary
CRO business
Foreign
Translational
Medipolis
exchange
profit
Research
Other
Clinical (incl.
business
business
profit and
total
Preclinical
loss
PPD-SNBL)
Q3 FY2022/3
39.2
9.3
-4.9
0.1
4.9
-1.8
46.8
22.4
6.2
-4.5
-0.4
-5.0
-2.3
16.4
Q3 FY2021/3
+16.8
-0.4
+30.3
Yoy changes
+3.1
+0.5
+9.9
+0.4
（ 100 million of yen）
+9.9 +0.4
+3.1 ▲0.4 +0.5
+16.8
As of 31/12/2020
5.31 stronger yen ⇒ FX loss of 500 million yen
As of 31/12/2021
4.30 weaker yen ⇒ FX profit of 490 million yen
16.4
FY21/3
Other
FY22/3
Clinical (incl.
Preclinical
Translational
Medipolis
FX profit
Q3
Q3
PPD-SNBL)
Research
and loss
株式会社新日本科学 Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 3
2. Revisions to Full-year Forecasts for FY2022/3
(announced on Feb 2, 2022)
株式会社新日本科学 Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 4
This is an excerpt of the original content. To continue reading it, access the original document here .
Attachments
Original Link
Original Document
Permalink
Disclaimer
Shin Nippon Biomedical Laboratories Ltd. published this content on 02 February 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 02 February 2022 06:08:12 UTC .
Jefferies Cuts Shin Nippon Biomedical Laboratories' EPS Estimates by 37% on 'Disappointing' Guidance, Weak Translational Research Unit
05/07
MT
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 1,500 Yen From 2,800 Yen
05/07
MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025
08/05
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025
08/05
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
02/02
CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval
18/01
MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024
07/11
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
02/23/02
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
02/23/02
CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting
15/23/15
CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
08/23/08
CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen
29/23/29
MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
08/23/08
CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen
18/23/18
MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals
18/23/18
MT
Sector Update: Health Care Stocks Higher Premarket Monday
17/23/17
MT
Bank Earnings in Focus as US Equity Futures Tread Water
17/23/17
MT
Top Premarket Gainers
17/23/17
MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical
17/23/17
MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.
17/23/17
CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
31/23/31
CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023
31/23/31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
More about the company
Last Close Price
1,354
JPY
Average target price
1,500
JPY
Spread / Average Target
+10.78%
Consensus
1st Jan change
Capi.
-20.26% 351M +18.97% 45.34B +41.98% 40.42B -10.06% 37.92B +31.15% 31.75B -7.79% 27.71B +13.32% 26.52B +43.05% 13.96B +31.28% 12.44B -7.41% 11.26B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
